Mandatory Metabolic Syndrome Check In Japan Provides Opportunities For Pharma Companies
This article was originally published in PharmAsia News
Starting this April, Japanese health insurers will be required to provide annual health checks to beneficiaries 40-74 years old in an effort to reduce the number of metabolic syndrome patients. Pharmaceutical companies such as Novartis, Novo Nordisk and Pfizer have leveraged this new requirement to launch various public relations campaigns. Novartis Japan has sponsored a campaign to raise public awareness of hypertension. Novartis cites that among 350 million hypertension patients in Japan, only 7.8 million are receiving treatment. Danish company Novo Nordisk, the world's top insulin drug maker, has conducted a survey on lifestyle diseases among working Japanese ages 30 to 40, and found that on average 32 is the age for people to have the tendency of becoming overweight. And with an April launch of a smoking cessation drug, Pfizer has banned employee smoking inside the company as a measure to prevent smoking caused lifestyle diseases. (Click here for more-Japanese language
You may also be interested in...
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.